Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors.

Matteo Simonelli(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Rita De Sanctis(Humanitas University), Francesco De Vincenzo(European University of Rome), Nicola Personeni(IRCCS Humanitas Research Hospital), Paolo Andrea Zucali(Humanitas University), Giovanna Masci(Humanitas University), Lorenza Rimassa(Humanitas University), Monica Bertossi(Humanitas University), Elena Lorenzi(Humanitas University), Matteo Perrino(IRCCS Humanitas Research Hospital), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Chiara Tronconi(Ospedale San Carlo), Monica Zuradelli(Humanitas University)
Journal of Clinical Oncology
May 20, 2011
10.1200/jco.2011.29.15_suppl.2521
Cited by 1

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743